Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Invest 4 Wealth University
Posted On: 09/24/2012 8:17:49 AM
Post# of 405
Avatar
Posted By: fitzkarz
Re: Big Tuna #149

Panic sell on PPHM!




  • QUICK LINKS :

  • Upcoming Dividends

  • EPS Movers

  • Top Upgrades

  • Buffett's Stocks

  • FREE SI Newsletters




Send to a Friend
Buy Stocks for $4 - $100 Bonus - ING DIRECT Investing


Peregrine Pharmaceuticals (PPHM) Discovered Major Discrepancies in Treatment Group Coding


Article Stock Quotes (1) Comments (0)






FREE Breaking News Alerts from StreetInsider.com!


E-mail Address





Top News Most Read Highlighted



  • Foxconn Shuts Product at iPhone Facility Following Massive Worker Riot, No Deaths Reported

  • U.S. Commences Probe into Questcor (QCOR) Over Marketing Practices

  • TiVo (TIVO), Verizon (VZ) Enter Patent Settlement; Verizon to Pay $250.4M

  • Top 10 News Items 09/17 - 09/21: Consumers Line UP for iPhone 5; Norfolk Southern Issues Warning; Noted Financial Exec Retires; BoJ Joins Easing Party

  • Apple's (AAPL) iPhone 5 Greeted With Massive Demand








September 24, 2012 7:32 AM EDT




PPHM Hot Sheet

Price: $5.39 --0%

Overall Analyst Rating:
BUY ( = Flat)

Revenue Growth %: -24.9%


Peregrine Pharmaceuticals (NASDAQ: PPHM ) said during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments. Due to the double-blind nature of the trial, Peregrine was not permitted to have access to either patient group assignments or related product coding information. As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

This discrepancy is specific to this trial and will have no impact on other ongoing bavituximab trials.

Peregrine intends to communicate further as soon as it is able to determine the impact of this issue. In the meantime, investors should not rely on clinical data that the company disclosed on or before September 7, 2012 from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this Phase II trial.


(0)
(0)






I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg



  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site